Latest DrugResistantEpilepsy News and Updates : DrugResistantEpilepsy updates, DrugResistantEpilepsy News , DrugResistantEpilepsy around the world

Nishadil

Washington | 26°C (overcast clouds)

Truist Ignites Excitement for Rapport Therapeutics (RAPP) with New 'Buy' Rating and $21 Price Target

Top story

Truist Ignites Excitement for Rapport Therapeutics (RAPP) with New 'Buy' Rating and $21 Price Target

In focus

Latest feed

A New Dawn for Epilepsy Patients: Rapport's Promising Drug Advances to Phase 3 Trials

Latest headlines

Load more